http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-097023-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c56417b20d0561e41e7a4e886b502cbc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-525 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415 |
| filingDate | 2014-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c903efedd8fd7ac80d814bb4396a529 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5b3cd6228a564be63708ac25c093d70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5bbd811627e3ed72664c282b9e7e89e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7db6899723848c03e70e6d172e4b1f28 |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-097023-A1 |
| titleOfInvention | COMPOSITION FOR THE MANAGEMENT OF NAUSE AND VOMITS, METHOD FOR RELIEFING THEM, PHARMACEUTICAL DOSAGE SYSTEM |
| abstract | Pharmaceutical dosage system comprising (a) an effective amount of one or more of the following ingredients: (i) doxylamine, (ii) a doxylamine analogue, (iii) a doxylamine derivative, (iv) a prodrug of doxylamine, (v) a metabolite of doxylamine or (vi) a pharmaceutically acceptable salt of any of ingredients (i) to (v); (b) an effective amount of one or more of the following ingredients: (i) pyridoxine, (ii) a pyridoxine analogue, (iii) a pyridoxine derivative, (iv) a pyridoxine prodrug, (v ) a pyridoxine metabolite or (vi) a pharmaceutically acceptable salt of any of the ingredients (i) to (v); and (c) an effective amount of one or more compounds of formula (1) where R is H, PO₃⁻ or a remainder of formula (2). Useful for relieving nausea and vomiting, such as nausea and vomiting during pregnancy (NVP). Claim 1: A pharmaceutical dosage system characterized in that it comprises (a) between about 5 and about 40 mg of one or more of the following ingredients: (i) doxylamine, (ii) a doxylamine analogue, (iii) a derivative of doxylamine, (iv) a prodrug of doxylamine, (v) a metabolite of doxylamine or (vi) a pharmaceutically acceptable salt of any of ingredients (i) to (v); (b) between about 5 and about 80 mg of one or more of the following ingredients: (i) pyridoxine, (ii) a pyridoxine analogue, (iii) a pyridoxine derivative, (iv) a prodrug of the pyridoxine, (v) a pyridoxine metabolite or (vi) a pharmaceutically acceptable salt of any of the ingredients (i) to (v); and (c) between about 20 and about 100 mg of one or more compounds of formula (1) where R is a hydroxyl group, a phosphate group or a group of the formula (2), or a pharmaceutically acceptable salt thereof. Claim 2: The system according to claim 1, characterized in that R is a hydroxyl group. Claim 3: The system according to claim 1, characterized in that R is a phosphate group. Claim 21: The system according to any of claims 1 to 20, characterized in that the ingredients (a), (b) and (c) are in the same pharmaceutical composition. Claim 22: The system according to any of claims 1 to 20, characterized in that the ingredients (a), (b) and (c) are found in various pharmaceutical compositions. Claim 23: The system according to any one of claims 1 to 22, characterized in that it comprises an immediate release component and a delayed release component. Claim 28: The system according to claim 27, characterized in that the one or more oral dosage forms take the form of tablets, pills, capsules, solutions or fluid powders. Claim 29: A useful method for relieving nausea and vomiting in a human subject in need, characterized in that it comprises administering to the human subject a system according to any one of claims 1 to 28. Claim 39: An appropriate dosing system for relieve nausea and vomiting during pregnancy in a human subject, characterized in that it comprises (a) an effective amount of one or more of the following ingredients: (i) doxylamine, (ii) a doxylamine analogue, (iii) a doxylamine derivative, (iv) a doxylamine prodrug, (v) a doxylamine metabolite or (vi) a pharmaceutically acceptable salt of any of the ingredients (i) to (v); (b) an effective amount of one or more of the following ingredients: (i) pyridoxine, (ii) a pyridoxine analogue, (iii) a pyridoxine derivative, (iv) a pyridoxine prodrug, (v ) a pyridoxine metabolite or (vi) a pharmaceutically acceptable salt of any of the ingredients (i) to (v); and (c) an effective amount of one or more compounds of formula (1) wherein R is a hydroxyl group, a phosphate group or a group of the formula (2), or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2013-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.